Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics
This collaboration combines the strengths of both companies' technologies to develop a next generation immunotherapeutic treatment that could provide systemic anti-cancer effect and immunity, with minimal systemic side effects for the benefit of cancer patients.
Dr Gun-Britt Fransson, Chief Executive Officer of Alligator Bioscience, commented: "We are very pleased to work with BioInvent, a company with proven success in developing antibody-based drugs, and we believe that Alligator Biosciences technology and know-how will add a substantial value and success to this joint program. Further, it also confirms that Alligator Biosciences technology is valuable and needed for the development of next generation antibody based drugs". According to the terms, the parties will after an initial research phase share costs and revenues equally.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.